Caxton Associates LP Buys Shares of 7,033 PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Caxton Associates LP purchased a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 7,033 shares of the company’s stock, valued at approximately $430,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Principal Financial Group Inc. raised its position in shares of PROCEPT BioRobotics by 5.7% during the 4th quarter. Principal Financial Group Inc. now owns 10,588 shares of the company’s stock worth $444,000 after purchasing an additional 568 shares during the last quarter. Hsbc Holdings PLC increased its position in PROCEPT BioRobotics by 31.2% during the fourth quarter. Hsbc Holdings PLC now owns 106,870 shares of the company’s stock worth $4,479,000 after buying an additional 25,440 shares in the last quarter. Allianz Asset Management GmbH increased its position in PROCEPT BioRobotics by 42.9% during the fourth quarter. Allianz Asset Management GmbH now owns 96,635 shares of the company’s stock worth $4,050,000 after buying an additional 28,999 shares in the last quarter. PEAK6 Investments LLC raised its holdings in shares of PROCEPT BioRobotics by 163.1% in the fourth quarter. PEAK6 Investments LLC now owns 45,901 shares of the company’s stock worth $1,924,000 after acquiring an additional 28,453 shares during the last quarter. Finally, Seven Eight Capital LP purchased a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at $550,000. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 35,220 shares of PROCEPT BioRobotics stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $76.12, for a total transaction of $2,680,946.40. Following the transaction, the director now directly owns 23,963 shares of the company’s stock, valued at $1,824,063.56. The sale was disclosed in a filing with the SEC, which is available at this link. In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 35,220 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $76.12, for a total value of $2,680,946.40. Following the transaction, the director now directly owns 23,963 shares of the company’s stock, valued at $1,824,063.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kevin Waters sold 25,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $82.51, for a total value of $2,062,750.00. Following the completion of the sale, the chief financial officer now directly owns 96,096 shares of the company’s stock, valued at approximately $7,928,880.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 154,892 shares of company stock worth $12,134,665. 17.40% of the stock is currently owned by company insiders.

PROCEPT BioRobotics Stock Performance

NASDAQ:PRCT opened at $79.53 on Friday. PROCEPT BioRobotics Co. has a fifty-two week low of $24.83 and a fifty-two week high of $85.81. The firm’s 50 day moving average is $72.35 and its two-hundred day moving average is $63.64. The company has a market cap of $4.09 billion, a P/E ratio of -37.51 and a beta of 1.03. The company has a quick ratio of 6.49, a current ratio of 7.51 and a debt-to-equity ratio of 0.20.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.02. The firm had revenue of $53.35 million for the quarter, compared to analysts’ expectations of $50.10 million. PROCEPT BioRobotics had a negative return on equity of 37.85% and a negative net margin of 58.73%. The firm’s revenue for the quarter was up 61.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.56) earnings per share. Analysts expect that PROCEPT BioRobotics Co. will post -1.88 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on PRCT shares. Wells Fargo & Company boosted their target price on shares of PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. TD Cowen boosted their price objective on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Truist Financial upped their price objective on shares of PROCEPT BioRobotics from $74.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Bank of America lifted their target price on shares of PROCEPT BioRobotics from $80.00 to $94.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $78.17.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).